Five Prime Therapeutics (FPRX) Misses Q3 EPS by 30c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Five Prime Therapeutics (FPRX) Comments From Jefferies 'Data Not As Strong As We Like To See'
November 7, 2017 11:51 AM ESTJefferies maintains Buy on Five Prime Therapeutics (NASDAQ: FPRX) price target of $52.00.
Analyst Eun Yang says the high rates of cabira-associated SAEs are concerning and chooses to await full data presentation at SITC on this coming SAturday before revisiting the... More
Five Prime Therapeutics (FPRX) Selloff Unfounded - Nomura/Instinet
November 7, 2017 11:14 AM ESTNomura/Instinet maintains Buy on Five Prime Therapeutics (NASDAQ: FPRX) price target of $94.00.
Analyst Chris Marai defends the name noting durable IP activity is evident. The analyst reminds clients that cabria is also mechanistically more likely to price benefit to pancreatic patients in... More
